A new precision medicine platform for cancer diagnosis using whole genome and transcriptome sequencing.
Official title: Isabl GxT: A clinically actionable whole genome and transcriptome precision medicine platform
Funded at Isabl INC. · NIH-10815789 · Data updated 2026-11-12
This study is working on a new test that uses advanced technology to help doctors better understand and diagnose cancers in kids and those with rare types of cancer, so they can provide more effective treatments and improve patient care.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Isabl INC. NIH-funded |
| Lab location | 1 site (New York, UNITED STATES) |
| Project start | April 1, 2023 |
| Project end | March 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $991,890 |
| NIH project number | 5R44CA281474-02 |
| Project ID | NIH-10815789 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are pediatric patients and individuals with rare cancers who require advanced genomic testing for their diagnosis.
✕Less likely to help
Patients with common cancers or those who do not require genomic testing may not benefit from this research.
What this research studies
This research focuses on developing a cutting-edge diagnostic test that utilizes whole genome and transcriptome sequencing specifically for pediatric and rare cancer patients. The Isabl GxT platform integrates genomic data with advanced data science techniques to provide timely and actionable insights for clinicians. By conducting analytical and clinical validity studies, the project aims to enhance the accuracy and utility of cancer diagnostics, ultimately leading to better patient outcomes. The initiative also seeks to expand the test's application to various biospecimen types, making it a versatile tool in oncology.
Why it matters
Potential benefit: If successful, this research could significantly improve cancer diagnosis and treatment options for pediatric and rare cancer patients.
How similar studies have gone: Other research has shown promise in utilizing genomic sequencing for cancer diagnostics, indicating a strong potential for success with this innovative approach.
Where this research is happening
-
Isabl INC.
New York, United States Active
Researchers
- Principal investigator: Medina, Juan Santiago — Isabl INC.
- Study coordinator: Medina, Juan Santiago
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.